Based on this evidence, TA was incorporated by the National Comprehensive Cancer Network into their guidelines for medically inoperable NSCLC patients with multiple lung cancers, no disease outside the chest, N0-1 status, limited (3 to 5) metastases, limited locoregional recurrence, limited (3 to 5) recurrence of distant metastases, and limited (3 to 5) sites of progression after therapy targeted to the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) [29]. This evidence concerns the gene ALK and lung cancer.